Delving into the Latest Updates on Ezatiostat Hydrochloride Liposomal with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Liposomal Drug

Synonyms

TLK199 HCl Liposomes

Target

GSTP1

Action

inhibitors

Mechanism

GSTP1 inhibitors(Glutathione S-transferase Pi inhibitors)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Myelodysplastic SyndromesNeutropenia, Severe Chronic

Originator Organization

Telik, Inc.

Active Organization-

Inactive Organization

Telik, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented significant cytopenia for at least two months by the IWG criteria are eligible.

Start Date01 May 2008

Sponsor / Collaborator

Telik, Inc.

NCT00035867

/ CompletedPhase 1/2

Phase 1-2a Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

The purpose of this study is to determine the safety and efficacy of TLK199 in patients with myelodysplastic syndrome (MDS).

Start Date01 Apr 2002

Sponsor / Collaborator

Telik, Inc.

100 Clinical Results associated with Ezatiostat Hydrochloride Liposomal

Login to view more data